ArticleBiochemistry and biophysics reports2026
NOHA as a key biomarker to link NOS2 activity to immune checkpoint and cytokine signaling in ER-negative breast cancer.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Estrogen receptor-negative (ER-) breast cancer remains clinically challenging due to its aggressive behavior, lack of targeted therapies, and limited biomarker tools for diagnosis and disease monitoring. While immune checkpoint markers (such as PD-L1) and inflammatory cytokines (viz., IL8) offer insight into tumor immune dynamics, their clinical application is hampered by tissue-dependence and/or biological variability. We have previously delineated N Methods: Three-dimensional (3D) spheroid cultures were generated from ER- and ER + breast cancer cell lines of African American (AA) and Caucasian (CA) origin, as well as healthy control cells. 3D spheroids were maintained for 7 weeks, with weekly measurements of their medium NOHA as well as lysates for cellular NOHA, NOS2 activity, total nitrites, PD-L1, and IL-8. Quantification was performed using validated ELISA and fluorometric assays. Statistical comparisons were performed using ANOVA with post-hoc testing. Results: ER- spheroids exhibited a progressive ≥1-fold increase in cellular NOS2, total nitrites, PD-L1, and IL-8, accompanied by a ≥1-fold decrease in both cellular and medium NOHA over 7 weeks (p < 0.01). No significant changes were observed in ER + or control spheroids. The ratio means of cellular PD-L1/medium NOHA and cellular IL-8/medium NOHA increased significantly in ER- groups, with AA-derived ER- 3D spheroids demonstrating ≥43.8 % and ≥48.4 % higher mean ratios, respectively, compared to ER- CA-derived counterparts (p < 0.01). A corresponding analysis comparing ratio means of cellular PD-L1/cellular NOHA and cellular IL-8/cellular NOHA showed a similar pattern, with ≥52.4 % and ≥55.9 % higher mean ratios in ER- groups, with AA-derived ER- 3D spheroids, than in ER- CA group (p < 0.01). Discussion: These findings identify NOHA as a potential non-invasive biomarker that reflects dynamic immuno-inflammatory changes in ER- breast cancer. The inverse relationship between NOHA and both PD-L1 and IL-8 suggests an inflammatory loop driven by NOS2 activity. The pronounced effects in AA-derived ER- spheroids align with known disparities in tumor aggressiveness and suggest future NOHA clinical utility potential in racially diverse populations. Further in vivo validation is warranted to support and confirm such clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.